Statin Combined with Amlodipine Treats Primary Aldosteronism

Conditions studied

Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist, Hypertension

About this study

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

Interventions

• Drug: Simvastatin combined with Amlodipine besylate — 6-month treatment of Simvastatin combined with Amlodipine besylate
• Drug: Simvastatin combined with Spironolactone and Amlodipine besylate. — 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
• Drug: Amlodipine besylate combined Spironolactone — 6-month treatment of Amlodipine besylate combined with Spironolactone

Primary outcomes

• changes in plasma aldosterone levels (6 month)
• changes in 24-hour urinary aldosterone levels (6 month)

Eligibility information

Study locations

• No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China, Chongqing, Chongqing Municipality 400042 China